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Abstract
HLA-G is a non-classicalMHCclass Ibmolecule predominantly expressed in cytotrophoblasts and under
pathological conditions also in chronically inflamed and in malignant tissues. Recently an increased
expressionofHLA-Gwas found inulcerativecolitis (UC), butnot inCrohn’sdisease (CD). TheHLA-G gene
is located in IBD3, a linkage region for inflammatory bowel disease (IBD). A 14-bp deletion
polymorphism (Del1/Del2) within exon 8 of the HLA-G gene might influence transcription activity and
is therefore of potential functional relevance. To investigate whether the 14-bp deletion polymorphism
is associated with IBD, 371 patients with CD, 257 patients with UC and 739 controls were genotyped.
The heterozygous genotype (P 5 0.031) and the Del1 phenotype (P 5 0.038) were significantly
increased, whereas the homozygous Del2 phenotype (P 5 0.038) was significantly decreased in UC
when compared with CD. Thus, the 14-bp deletion polymorphism within the HLA-G gene displayed
significant differences between UC and CD. Moreover, a significant increase of the Del1 allele
(P 5 0.002) and the Del1/Del1 genotype (P 5 0.013) and a consecutive decrease of the Del2/2
genotype (P5 0.024) were observed in those CD cases positive for ileocecal resection. Thus, a potential
effect of the HLA-G gene in IBD may affect both UC and CD. Other polymorphisms linked to the 14-bp
deletion polymorphism might also contribute to immunopathogenesis. As there are several partly
functional polymorphisms within the promoter region potentially influencing HLA-G expression, further
studies in IBD are necessary in the context of differential expression of HLA-G between UC and CD.
Introduction
Chronic inflammatory bowel disease (IBD) comprises the
two disease entities Crohn’s disease (CD) and ulcerative co-
litis (UC) (1, 2). CD is characterized by a segmental chronic
granulomatous inflammation of the whole intestinal wall
predominantly located in the terminal ileum and potentially
affecting every part of the gastrointestinal tract (3). In con-
trast, the inflammation in UC is more continuous displaying
crypt abscesses and ulcers, being restricted to the intestinal
mucosa and the disorder occurs within the colorectum (4).
The etiology of IBD remains unclear, but environmental
factors, e.g. the microbial flora, as well as genetic factors
play important roles for disease pathogenesis, resulting in
dysregulation of the intestinal mucosal immune system (3,
4). Linkage analyses revealed several linkage regions on
different chromosomes (5, 6). The first linkage region for
IBD was IBD1 on chromosome 16p containing the NOD2/
Correspondence to: J. Glas; E-mail: juergen.glas@med.uni-muenchen.de Received 22 November 2006, accepted 22 February 2007
Transmitting editor: A. Falus Advance Access publication 19 April 2007
CARD15 gene, which has been the first gene, in which
mutations reproducibly were associated with CD in Cauca-
sians (7, 8). The IBD3 region has been linked to chromo-
some 6p21, a region containing the MHC (9). The MHC is
a region of an extremely high abundance of genes compris-
ing the MHC class I and class II genes and further genes,
named MHC class III, exhibiting functions in immunological
processes such as the cytokines tumor necrosis factor
(TNF)-a, TNF-b and the heat shock proteins. It is not clear
so far, which genes within the MHC family contribute to the
pathogenesis of IBD, and thus, diverse genes in this region
can be considered as functional and positional candidate
genes for IBD.
HLA-G is a non-classical MHC class I molecule displaying
restricted tissue expression and low polymorphism (10, 11).
Under normal conditions expression of the HLA-G protein is
restricted to the feto-maternal interface on the extravillous
cytotrophoblast protecting the fetal semi-allograft against the
maternal immune system (11, 12) and to the thymus in adults
(11, 13). HLA-G expression is up-regulated under pathologi-
cal conditions in inflammatory diseases such as psoriasis
and atopic dermatitis (14, 15), in viral infection (16), malignan-
cies (17) and organ transplants (18). The main function of
HLA-G is suppression of several immune processes carrying
out inhibitory effects on cytolysis by NK cells and CTL, T cell
proliferative responses and maturation of dendritic cells (11).
These inhibitory effects are mediated by ligation of HLA-G
and inhibitory receptors such as ITL2, ITL4 and KIR2DL4 on
the surface of immunocompetent cells (11, 19). HLA-G exhib-
its low allelic polymorphism in comparison with the classical
MHC class I molecules. Currently, 15 HLA-G alleles are known
at the nucleotide level resulting in six different proteins (11,
20, 21). Seven protein isoforms, four membrane bound (HLA-
G1, -G2, -G3 and -G4) and three soluble (HLA-G5, -G6 and
-G7), are generated by alternative splicing (22–24). Further
nucleotide polymorphisms have been described within the
non-coding region of the HLA-G gene, 18 single-nucleotide
polymorphisms (SNPs) in the promoter region and a 14-bp
deletion polymorphism in exon 8 (rs16375) encoding for the
3# untranslated region (25, 26). The latter polymorphism is po-
tentially functional influencing transcript levels and splicing
(11, 27). Recently, a differential pattern of HLA-G expression
in CD and UC has been shown. By immunohistochemistry, in-
creased HLA-G surface expression has been only detected
in UC, whereas HLA-G expression was absent in CD and also
in healthy controls (28). These findings suggest a role of HLA-
G in the immunopathogenesis of IBD, and analysis of HLA-G
expression possibly can be used for diagnostic purposes to
distinguish between CD and UC in cases of indeterminate co-
litis. Considering the localization in the linkage region IBD and
its immunosuppressive function, HLA-G is an excellent candi-
date gene for IBD. Thus, the present study aimed to investi-
gate whether the 14-bp deletion polymorphism within the
HLA-G gene is associated with IBD.
Methods
Study population
The study population comprised 371 patients with CD, 257
patients with UC and 739 healthy unrelated blood donors
serving as controls. The patients were recruited from two ter-
tiary referral centers (226 CD and 155 UC cases from the
university hospital of the University of Munich and 145 CD
and 102 UC cases from the university hospital of the Univer-
sity of Bochum). All study participants were Caucasians of
German origin and gave their written informed consent. CD
or UC was diagnosed by conventional clinical, radiological,
endoscopic and histological criteria. Cases with indetermi-
nate colitis were excluded. There were no significant differ-
ences between CD or UC, respectively, and controls with
respect to age or gender. Clinical characteristics were avail-
able from 176 CD and 119 UC patients recruited from the
university hospital of the University of Munich. Hundred and
thirty-nine patients with CD displayed a fibrostenotic (fistu-
lae, stenoses or both) and 37 patients an inflammatory phe-
notype (no fistulae and no stenoses). In 132 CD patients,
the disease was located in both the ileum and the colon,
whereas in 44 only either the ileum or the colon was af-
fected. Of 176 CD patients, 66 had undergone ileocecal re-
section. In the group of UC patients, 68 displayed
a pancolitis ulcerosa, whereas in 51 cases, the inflammatory
process was either restricted to the rectosigmoid or to the
left hemicolon.
Genotyping and statistical analysis
DNA was obtained from peripheral blood anti-coagulated
with EDTA using in part the QIAamp DNA Blood Mini kit
(Qiagen, Hilden, Germany) and in part the salting out proce-
dure. The 14-bp deletion polymorphism within the HLA-G
gene was genotyped using PCR and agarose gel electro-
phoresis. The total volume of the PCR was 10 ll, containing
50 ng of genomic DNA, 13 PCR buffer (Qiagen), 0.5 mM of
a deoxynucleoside triphosphate mix (Sigma, Steinheim, Ger-
many), 0.5 U of HotStarTaqTM DNA polymerase (Qiagen)
and 5 pmol of each primer (TIB MOLBIOL, Berlin, Germany).
The final concentration of MgCl2 was 1.5 mM. The PCR com-
prised an initial denaturation step (95C for 15 min), 35
cycles (94C for 30 s, 60C for 30 s and 72C for 30 s) and
a final extension step (72C for 10 min). PCR amplificates
were analyzed by electrophoresis in 4% NuSieve 3:1
(Cambrex, Rockland, ME, USA) agarose gels stained with
ethidium bromide. The genotyping results were additionally
confirmed by sequencing several DNA samples of individu-
als displaying the three possible genotypes using identical
PCR conditions. The HLA-G allele lacking the 14 bp in exon
8 is named Del+, whereas the allele containing this se-
quence is called Del.
Allele frequencies were tested for Hardy–Weinberg equi-
librium. Statistical analysis was performed using Parson’s v2
test with Yates correction (SPSS version 13.0, SPSS Inc., Chi-
cago, IL, USA). P values < 0.05 were considered significant.
Results
Allele, genotype and phenotype frequencies of the 14-bp
deletion polymorphism within the HLA-G gene in UC and CD
The frequencies of the 14-bp deletion polymorphism within
the HLA-G gene in UC and CD, respectively, displayed no
significant associations when compared with the control
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group. The frequencies of the Del+ allele were 62.5% in UC,
60.8% in CD and 61.2% in the control group. The homozy-
gous Del+ genotype was observed in 35.4% of UC cases,
in 38.3% of CD cases and in 36.0% of the controls and the
homozygous Del genotype was present in 10.5% of UC
cases, in 16.7% of CD cases and in 13.5% of the controls,
whereas the heterozygous genotype was found in 54.1% of
UC cases, in 45.0% of CD cases and in 50.5% of the con-
trols. The genotype frequencies were in agreement with the
Hardy–Weinberg equilibrium. Yet, when comparing the UC
and the CD groups among each other, the heterozygous
genotype was significantly increased (P = 0.031), whereas
the homozygous Del genotype was significantly decreased
(P = 0.038) in UC compared with CD. The frequencies of the
Del+ phenotype were 89.5% in UC, 83.3% in CD and 86.5%
in the control group and the frequencies of the Del pheno-
type were 64.6% in UC, 61.7% in CD and 64.0% in the
control group. Analogous to the genotype frequencies the
phenotype frequencies displayed no significant differences
between UC and CD, respectively, when compared with the
control group. When comparing UC and CD among each
other, the Del+ phenotype was significantly increased in UC
compared with CD (P = 0.038). All allele, genotype and
phenotype frequencies of the HLA-G 14-bp deletion poly-
morphism in UC and CD as well as in the control group are
depicted in Tables 1 and 2.
Allele, genotype and phenotype frequencies of the 14-bp
deletion polymorphism within the HLA-G gene in CD as
stratified for disease-associated mutations within the
NOD2/CARD15 gene
Genotyping results for the three common mutations R702W,
G908R and L1007fsinsC within the NOD2/CARD15 gene
associated with CD were available in 367 (98.9%) of the
371 CD patients. Hundred and forty-two (38.7%) of the CD
cases displayed at least one mutated NOD2/CARD15 allele.
These cases were classified as positive for NOD2/CARD15
mutations (NOD2/CARD15+) and compared with the re-
maining 225 cases containing only wild-type NOD2/CARD15
alleles classified as negative for NOD2/CARD15 mutations
(NOD2/CARD15). The allele frequencies of the 14-bp dele-
tion polymorphism within the HLA-G gene showed no signifi-
cant differences in the CD group according to the NOD2/
CARD15 mutation status, and the Del+ allele was observed
in 62.0% of the NOD2/CARD15+ cases and in 59.8% of the
NOD2/CARD15 cases. Moreover, genotype and phenotype
frequencies of the HLA-G 14-bp deletion polymorphism dis-
played no significant differences depending on the NOD2/
CARD15 mutation phenotype. The allele, genotype and phe-
notype frequencies of the HLA-G 14-bp deletion polymor-
phism in CD stratified for the NOD2/CARD15 mutation
status are depicted in Table 3.
Allele, genotype and phenotype frequencies of the 14-bp
deletion polymorphism within the HLA-G gene in CD and in
UC stratified for clinical phenotypes
The group of patients with CD was stratified for disease be-
havior (fibrostenotic versus inflammatory phenotype), for dis-
ease location and the need for ileocecal resection. In the
subgroup of CD patients with the fibrostenotic phenotype,
the frequency of the Del+ allele was 59.7%, whereas in the
subgroup with an inflammatory phenotype, the frequency of
this allele was 54.1%. Considering disease location/extent in
the CD patients, the Del+ allele was found in 59.5% of those
cases displaying an involvement of both ileum and colon
and in 58.0% of cases displaying an involvement of either
the ileum only or the colon only. Thus, the allele and also
the genotype frequencies did not significantly differ after
stratification for disease behavior or for disease location/ex-
tent in CD. Furthermore, the CD patients were stratified for
the need of ileocecal resection. In the subgroup of patients
with ileocecal resection compared with those cases without
ileocecal resection, the frequencies of the Del+/Del+ geno-
type (47.0 versus 27.3%, P = 0.013) and of the Del+ allele
(69.7 versus 52.7%, P = 0.002) were significantly increased,
whereas the frequency of the Del/Del genotype (7.6 ver-
sus 21.8%, P = 0.024) was significantly decreased. In the
patients with UC cases with a disease extent restricted to
the rectosigmoid or the left hemicolon were compared with
Table 1. Allele frequencies of the 14-bp deletion polymor-
phism (Del+/Del) within the HLA-G gene in UC and CD
UC, n = 514 (%) CD, n = 742 (%) Controls, n = 1478 (%)
Del+ 321 (62.5) 451 (60.8) 905 (61.2)
Del 193 (37.5) 291 (39.2) 573 (38.8)
Table 2. Genotype and phenotype frequencies of the 14-bp
deletion polymorphism (Del+/Del) within the HLA-G gene in
UC and CD
UC, n = 257
(%)
CD, n = 371
(%)
Controls, n = 739
(%)
Del+/Del+ 91 (35.4) 142 (38.3) 266 (36.0)
Del+/Del* 139 (54.1) 167 (45.0) 373 (50.5)
Del/Del** 27 (10.5) 62 (16.7) 100 (13.5)
Del+*** 230 (89.5) 309 (83.3) 639 (86.5)
Del 166 (64.6) 229 (61.7) 473 (64.0)
*P = 0.031, **P = 0.038, ***P = 0.038 (UC versus CD).
Table 3. Allele, genotype and phenotype frequencies of the
14-bp deletion polymorphism (Del+/Del) within the HLA-G
gene in CD after stratification for presence of mutations
(R702W, G908R and L1007fsinsC) within the CARD15/NOD2
gene (CARD15/NOD2+)
CARD15/NOD2+ (%) CARD15/NOD2 (%)
Allele n = 284 n = 450
Del+ 176 (62.0) 269 (59.8)
Del 186 (38.0) 181 (40.2)
Genotype/phenotype n = 142 n = 225
Del+/Del+ 55 (38.7) 83 (36.9)
Del+/Del 66 (46.5) 103 (45.8)
Del/Del 21 (14.8) 39 (17.3)
Del+ 121 (85.2) 186 (82.7)
Del 87 (61.3) 142 (63.1)
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those cases displaying a pancolitis ulcerosa. The frequen-
cies of the Del+ allele were 57.8% in the subgroup with a re-
stricted disease extent and 60.3% in the subgroup with
pancolitis ulcerosa and thus displayed no significant associ-
ation. All allele and genotype frequencies in CD and UC
stratified for clinical phenotypes are depicted in Tables 4
and 5.
Discussion
In the present study, a deletion polymorphism (rs16375)
within the HLA-G gene has been investigated in IBD for the
first time. As the HLA-G gene is located in the linkage region
IBD3 and it is involved in immunological processes, it repre-
sents an excellent positional and functional candidate gene
for IBD. Recently, Torres et al. (28) found high immunohisto-
chemical expression of HLA-G in all segments of the gastro-
intestinal tract in 100% of cases with UC, whereas HLA-G
expression was completely absent in all cases of CD as well
as in healthy controls. This differential expression pattern of
HLA-G is possibly influenced by genetic variations within
the HLA-G gene. In the present study, the 14-bp deletion
polymorphism within the HLA-G gene (Del+/Del), a variation
potentially influencing transcription activity (27), has been in-
vestigated in 253 patients with UC and 371 patients with CD.
The allele, genotype and phenotype frequencies of the 14-
bp deletion polymorphism in UC or CD, respectively, dis-
played no significant differences when compared with
a group of 739 healthy controls. The allele frequencies in
the control group found herein were similar to those
detected in the control groups of other studies (25, 29, 30).
Yet, when the UC and CD groups were compared among
each other, the Del+ phenotype and the heterozygous Del+/
 genotype were significantly increased in UC, whereas the
frequency of the homozygous genotype Del/ was signifi-
cantly lower in UC than in CD. These findings are consistent
with the differential expression pattern of HLA-G in UC com-
pared with CD as shown by Torres et al. (28) as well as by
O’Brien et al. (27), where decreased HLA-G expression was
observed in placenta samples of cases with homozygous
Del genotype. It has to be taken into account that no geno-
typing data were included in the study of Torres et al. (28)
and it is therefore unknown, whether different HLA-G expres-
sion in the intestine is influenced by genetic variations. It has
also to be considered that the present study and the study
of Torres et al. (28) have been performed in two different
populations, a German population versus a population of
Spanish origin. Even though both are of Caucasian origin,
the genetic background potentially could differ to some ex-
tent. Moreover, though the data of Torres et al. (28) offer an
interesting finding toward a different immunopathogenesis in
UC and CD, these results have to be confirmed in further in-
dependent studies and should be correlated with functional
polymorphisms within the HLA-G gene.
The differences of the 14-bp deletion HLA-G polymor-
phism between UC and CD found herein gives evidence for
a contribution of the HLA-G gene in the pathogenesis of
IBD; however, this genetic effect might be rather weak and
the power of the present study might be too low to detect
significant differences in comparison to the control group.
Due to its weak observed genetic effect, the 14-bp deletion
polymorphism itself cannot exclusively be responsible for
the observed gastrointestinal HLA-G expression in UC
patients, but other polymorphisms and factors contribute to
the pathogenesis of IBD. In the promoter region of the HLA-
G gene, several SNPs partly of functional relevance and
partly associated with increased miscarriage rates have
been described (26). As strong linkage disequilibria exist
between the 14-bp deletion polymorphism and SNPs within
the HLA-G promoter, the SNP alleles or SNP haplotypes of
the promoter region are potentially associated with the differ-
ential expression of HLA-G between UC and CD and further
studies are indicated to clarify this issue. Moreover, varia-
tions in other genes, which could influence the transcription
of HLA-G or HLA-G protein synthesis also might account for
differential HLA-G expression. Further candidate genes
within this context might be those genes encoding receptors
recognizing HLA-G. The genes coding for the receptors
ILT2, ILT4 and KIR2DL4 are located within a linkage region
for IBD on chromosome 19 and particularly the KIR genes
display substantial polymorphism (31–33).
As the NOD2/CARD15 gene has been the first gene asso-
ciated with IBD, in particular with CD (7, 8), the CD group
has been stratified for the presence of at least one of the
three common CD-associated NOD2/CARD15 mutations
(R702W, G908R and L1007fsinsC). However, the distribution
of the 14-bp deletion polymorphism in the HLA-G gene dis-
played no significant differences between cases positive and
those negative for NOD2/CARD15 mutations and thus, no evi-
dence for an interaction between HLA-G and NOD2/CARD15
Table 4. Genotype and allele frequencies of the 14-bp deletion polymorphism (Del+/Del) within the HLA-G gene in CD after
stratification for clinical phenotypes (disease behavior, disease location and ileocecal resection)
Genotype/allele Disease behavior Disease location/extent Ileocecal resection
Fibrostenotic
phenotype,
n = 139/278 (%)
Inflammatory
phenotype,
n = 37/74 (%)
Location in both
ileum and colon,
n = 132/264 (%)
Location in ileum
only or in colon only,
n = 44/88 (%)
Ileocecal resection,
n = 66/132 (%)
No ileocecal resection,
n = 110/220 (%)
Del+/Del+* 48 (35.5) 12 (32.4) 46 (34.9) 15 (34.1) 31 (47.0) 30 (27.3)
Del+/Del 70 (50.4) 16 (43.2) 65 (49.2) 21 (47.7) 30 (45.4) 56 (50.9)
Del/Del** 21 (15.1) 9 (24.3) 21 (15.9) 8 (18.2) 5 (7.6) 24 (21.8)
Del+*** 166 (59.7) 40 (54.1) 157 (59.5) 51 (58.0) 92 (69.7) 116 (52.7)
Del 112 (40.3) 34 (45.9) 107 (40.5) 37 (42.0) 40 (30.3) 104 (47.3)
*P = 0.013, **P = 0.024, ***P = 0.002 (ileocecal resection versus no ileocecal resection).
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genes could be found. Both the CD and the UC patients were
additionally stratified for specific clinical phenotypes. In the
UC patients, no association could be detected after strati-
fication for disease location and extent. The frequencies of
genotypes and alleles of the 14-bp deletion HLA-G polymor-
phism were comparable in the groups displaying a disease
extent confined to the ileum or to the colon only and in the
group with a pancolitis ulcerosa. The CD patients were strati-
fied for disease behavior (fibrostenotic versus inflammatory
subtype), for disease location/extent (ileal disease only or co-
lonic disease only versus ileocolonic disease) and for the
need of ileocecal resection. While after stratification for dis-
ease behavior and for disease extent no association could
be found, a significant association of the 14-bp deletion poly-
morphism was observed after stratification for the need of
ileocecal resection. In the subgroup of CD patients with ileo-
cecal resection, the frequency of the Del+/Del+ genotype
was 47.0% compared with 27.3% in patients without ileocecal
resection, whereas the two other genotypes were consecu-
tively decreased. The frequency of the Del+ allele was signifi-
cantly increased in CD patients with in relation to those
patients without ileocecal resection (69.7 versus 52.7%).
Since the frequency of the Del+ allele only displayed a sig-
nificant difference when comparing the subgroups after
stratification of CD patients for ileal resection to each other,
but not in the comparison of the whole group of CD patients
to the group of healthy controls, HLA-G may play a role in
modulating the course of CD rather than determining overall
susceptibility.
The relative contribution of the MHC to the overall genetic
risk was estimated as 64–100% in UC by linkage and epide-
miologic studies, whereas in CD the values were only
10–33% (5, 9, 34, 35). Considering the findings of the study
of Torres et al. (28), the results of the present study suggest
a potential role of HLA-G as a disease susceptibility gene
rather in UC than in CD, as in UC the tendency toward an
association of the HLA-G gene is more pronounced com-
pared with the total population of CD patients. HLA-G poten-
tially functions as a shield against inflammatory aggression
(16). It might contribute to tissue protection by inhibiting NK
cell activity and tissue infiltration by T cells and monocytes
shifting the balance between Th1 and Th2 cells toward the
Th2 pathway (11, 16, 36). A potential role of HLA-G in the
pathogenesis of UC is in line with the Th2 pathway rather
characteristic for UC (4). Further evidence for a role of HLA-
G in chronic Th2-driven inflammation is given by the identifi-
cation of HLA-G as a susceptibility gene for asthma includ-
ing an association of the 14-bp deletion polymorphism (37).
In UC, the increased expression of HLA-G might reduce
clearing of intestinal micro-organisms and therefore promote
a secondary chronic inflammation.
In conclusion, the present study found a significant differ-
ence of the distribution of the 14-bp deletion polymorphism
within the HLA-G gene between UC and CD. Thus, HLA-G
possibly plays a role in the immunopathogenesis of IBD.
However, as the genetic effect of the 14-bp deletion poly-
morphism observed in the present study is rather weak in
the populations of CD and UC patients as a whole, probably
further genetic factors interacting with HLA-G contribute to
IBD. Moreover, the association of this polymorphism with
ileocecal resection in CD suggests a role of HLA-G as a dis-
ease-modulating gene.
Abbreviations
CD Crohn’s disease
IBD inflammatory bowel disease
SNP single-nucleotide polymorphism
TNF tumor necrosis factor
UC ulcerative colitis
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